Icure Pharmaceutical Incorporation (175250) — Cash Flow Reinvestment Rate

Latest as of June 2020: 83.70x

Icure Pharmaceutical Incorporation (175250) has a Cash Flow Reinvestment Rate of 83.70x as of June 2020, reinvesting ₩16.36 Billion (capex ₩7.44 Billion plus investments ₩8.92 Billion) from operating cash flow of ₩195.44 Million. See Icure Pharmaceutical Incorporation free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

83.70x

(Capex + Investments) / Operating CF

Total Reinvested

₩16.36 Billion

Capex + Investments

Operating Cash Flow

₩195.44 Million

KRW

Capital Expenditures

₩7.44 Billion

KRW

Icure Pharmaceutical Incorporation Cash Flow Reinvestment Rate (2017–2017)

Historical reinvestment intensity for Icure Pharmaceutical Incorporation across 1 annual periods. For the full cash flow conversion analysis, see 175250 cash generation efficiency.

Annual Cash Flow Reinvestment Rate for Icure Pharmaceutical Incorporation (2017–2017)

Year-by-year capital reinvestment analysis for Icure Pharmaceutical Incorporation. See financial flexibility index of Icure Pharmaceutical Incorporation to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (KRW)	Operating CF	Capex	YoY Change
2017	9.20x	₩10.30 Billion	₩1.12 Billion	₩10.10 Billion	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow